Feel Well Again Blog

As a practicing psychiatrist, I recently encountered a study that fundamentally changed how I think about treating alcohol use disorder (AUD). The research by Morley et al. (2024) comparing topiramate with naltrexone represents the largest double-blind, randomized controlled head-to-head trial to date of these two medications. What I discovered has already begun influencing my clinical practice.

Why This Study Matters

To put this in perspective, imagine discovering that green apples have twice the nutritional value of red apples, plus additional benefits for weight loss and mood improvement. Before reading such a study, you’d be indifferent about which type of apple to choose—both are healthy. After reading it, the choice becomes clear: you’re going green.

That’s exactly how I feel about topiramate after reviewing this research. Previously, I relegated topiramate to second-tier status for AUD treatment, typically starting with naltrexone and considering topiramate only later. The study results suggest this approach may need updating.

Key Findings: Topiramate Shows Superior Outcomes

The 12-week study of 147 participants with AUD revealed several important findings:

Primary Outcomes:

• For heavy drinking days, there was a near-significant time-by-treatment interaction favoring topiramate
• For standard drinks per drinking day, topiramate showed significantly greater reduction compared to naltrexone

Secondary Benefits:

• Weight Management: Topiramate demonstrated superior BMI reduction compared to naltrexone
• Craving Reduction: Significantly greater reduction in alcohol craving with topiramate
• Liver Function: Greater improvement in gamma-glutamyltransferase (GGT), a liver enzyme that indicates alcohol damage, levels with topiramate

Safety Profile:

• Both medications were well-tolerated
• The topiramate group reported more paresthesia (tingling sensations in the skin) and attention difficulties
• There was no significant difference in medication discontinuation due to side effects

The Clinical Reality: It’s Not That Simple

Despite these promising results, I won’t be automatically recommending topiramate over all other AUD medications. Here’s why:

The Titration Challenge

The most significant practical limitation wasn’t highlighted in the main study but detailed in a supplementary document: topiramate requires a complex 6-week titration schedule.

• Week 1: 25mg PM
• Week 2: 50mg PM
• Week 3: 75mg (25mg AM, 50mg PM)
• Week 4: 100mg (50mg AM, 50mg PM)
• Week 5: 150mg (50mg AM, 100mg PM)
• Week 6-12: 200mg (100mg AM, 100mg PM)

Compare this to naltrexone’s elegance: 50mg daily from day one through day 365. No titration, no complex schedule.

Why Simplicity Matters in AUD Treatment

Patients with alcohol use disorders often struggle with:

• Medication adherence
• Following complex treatment plans
• Attending regular appointments

The six-week titration period means we can’t even assess topiramate’s effectiveness until week 6, whereas naltrexone’s effects can be evaluated immediately.

The Sinclair Method Advantage

Finally, naltrexone offers unique flexibility through the Sinclair Method—taking medication only on days when drinking is likely. This approach works particularly well for patients who:

• Have managed to control drinking in their daily routine
• Experience problems only at specific events (e.g., work conferences, social gatherings)
• Prefer as-needed rather than daily medication

This flexibility isn’t possible with topiramate due to its titration requirements and how it works in the brain.

Additional Clinical Considerations

Weight Management Benefits

An especially interesting finding was topiramate’s superior weight reduction compared to naltrexone. Given that the study participants had an average BMI of 28 (overweight), this could be clinically significant for many patients.

Clinical Note: While naltrexone alone didn’t show weight benefits in this study, it’s worth noting that naltrexone comprises half of Contrave (naltrexone + bupropion), an FDA-approved weight loss medication. For appropriate candidates, combining naltrexone with bupropion (brand name: Wellbutrin) might achieve similar weight management benefits.

Side Effect Profile

The study confirmed topiramate’s known side effects:

• Paresthesia: Tingling sensations (significantly more common than with naltrexone)
• Cognitive effects: Attention difficulties (topiramate is sometimes called “dopamax” in clinical circles due to attention-related side effects)
• Appetite suppression: Which may contribute to weight loss benefits

My Updated Clinical Approach

Based on this research, I’m adding topiramate as “Option E” to my AUD medication discussions, alongside:

• A) Naltrexone
• B) Acamprosate
• C) Gabapentin
• D) Disulfiram
• E) Topiramate (new addition)

When I’ll Consider Topiramate First-Line

• For patients seeking weight management alongside AUD treatment
• For those who’ve failed naltrexone or other first-line treatments
• For patients with good medication adherence history
• For those who can commit to the titration schedule

When I’ll Still Prefer Naltrexone

• For patients with poor medication adherence
• For those preferring as-needed dosing options
• For patients concerned about cognitive side effects
• When treatment simplicity is paramount

The Genetics Factor: No Clear Guidance Yet

The study also examined genetic markers (rs2832407 in GRIK1 for topiramate response, rs1799971 in OPRM1 for naltrexone response) but found no significant genotype effects on treatment response. This means we can’t yet use genetic testing to guide medication selection—clinical factors remain our primary decision-making tools.

This finding is important because previous smaller studies had suggested these genetic variants might predict who would respond better to each medication. The researchers specifically designed this study to test those earlier findings by prospectively dividing participants based on their genetics from the start, rather than looking back at genetic data after the fact. This more rigorous approach didn’t support the earlier promising results.

What this means for patients is that we’re still in the era of “trial and see what works” rather than precision medicine for alcohol use disorder. While disappointing, this actually reflects the complex reality of addiction treatment—response to medication depends on many factors including genetics, environment, psychology, and social support systems. A single genetic test simply can’t capture all of that complexity.

However, this doesn’t mean genetic research is a dead end. Future studies may identify multiple genetic markers that, when combined, could help predict treatment response. We’re also learning that pharmacogenetics—how genes affect drug metabolism and side effects—might be more useful than trying to predict efficacy alone. For now, though, the best approach remains careful clinical assessment and close monitoring of individual patient response.

Looking Forward: Real-World Validation Needed

While these study results are compelling, I need to see how they translate to my clinical practice. I’ll be gathering data on:

• Patient adherence to topiramate titration schedules
• Real-world effectiveness compared to study conditions
• Long-term tolerability
• Patient satisfaction and quality of life impacts

Over the next 1-2 years, I expect to gather sufficient data to decide whether to prescribe topiramate over naltrexone in additional cases. If my clinical experience aligns with the study findings—patients generally find topiramate helpful and worth the titration hassle—I may consider promoting it to first-line status.

The Clinical Reality

This study provides strong evidence that topiramate is at least as effective as naltrexone for AUD treatment, with superior outcomes in several important areas. However, the complexity of initiation and titration remains a significant practical hurdle.

The choice between these medications should be individualized based on:

• Patient’s adherence capabilities
• Weight management goals
• Tolerance for side effects
• Preference for dosing flexibility
• Previous treatment responses

As with many aspects of psychiatry, there’s no one-size-fits-all solution. But now I have stronger evidence to support topiramate as a viable first-line option for appropriate patients.